Abstract
DNAzymes (Dzs) are single-stranded DNA catalysts that specifically cleave the mRNA of targeted genes. Compared with other gene-silencing technologies, such as ribozymes, antisense oligonucleotide and small interference RNA (siRNA), DNAzymes have several advantages, including small molecular weight, diversity, low cost and relative stability in serum. With the evolution of molecular technology, the first DNAzyme was generated in vitro in 1994. From then on, DNAzymes have been studied in order to understand their structures, chemistry and biological applications. Particularly, DNAzymes have been widely applied as a new interference strategy in the treatment of many conditions, including cancer, viral diseases, and cardiovascular diseases. This review mainly summarizes the use of DNAzymes in the areas of cancer research and therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Breaker R R, Joyce G F. A DNA enzyme that cleaves RNA. Chem Biol, 1994, 1: 223–229
Baum D A, Silverman S K. Deoxyribozymes: Useful DNA catalysts in vitro and in vivo. Cell Mol Life Sci, 2008, 65: 2156–2174
Santoro S W, Joyce G F. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA, 1997, 94: 4262–4266
Dass C R, Choong P F M. Sequence-related off-target effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration. Oligonucleotides, 2010, 20: 51–60
Bhindi R, Fahmy R G, Lowe H C, et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol, 2007, 171: 1079–1088
Pecot C V, Calin G A, Coleman R L, et al. RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer, 2011, 11: 59–67
Yang L F, Lu Z X, Ma X Q, et al. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules, 2010, 15: 6127–6139
Lu Z X, Ma X Q, Yang L F, et al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett, 2008, 265: 226–238
Mitchell A, Crispin R D, Sun L Q, et al. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumor growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res, 2004, 32: 3065–3069
Zeng W Z, Deng L Y, Zhou R. Experimental study of targeting MMP-9 deoxyribozyme role of adhesion and migration in human lung adenocarcinoma cancer cell (in Chinese). Chin J Lung Cancer, 2008, 11: 765–768
Yang L F, Zeng W Z, Li D, et al. Inhibition of cell proliferation, migration and invasion by DNAzyme targeting MMP-9 in A549 cells. Oncol Rep, 2009, 22: 121–126
Min Z, Zhao H, Luo F Y, et al. IGF-II inhibitory DNAzymes inhibit the invasion and migration of hepatocarcinoma cells. Biotechnol Lett, 2011, 33: 911–917
Liang Z Y, Wei S Z, Guan J, et al. DNAzyme-mediated cleavage of survivin mRNA and inhibition of the growth of PANC-1 cells. J Gastroen Hepatol, 2005, 20: 1595–1602
Wiktorska M, Papiewska-Pajak L, Okruszek A, et al. DNAzyme as an efficient tool to modulate invasiveness of human carcinoma cells. Acta Biochim Pol, 2010, 57: 269–275
Choi B R, Gwak J, Kwon H M, et al. Oligodeoxyribozymes that cleave β-catenin messenger RNA inhibit growth of colon cells via reduction of β-catenin response transcription. Mol Cancer Ther, 2010, 9: 1894–1902
Yu S H, Wang T H, Au L C. Specific repression of mutant K-RAS by 10–23 DNAzyme: Sensitizing cancer cell to anti-cancer therapies. Biochem Biophys Res Commun, 2009, 378: 230–234
Qu Y, Zhang L, Mao M, et al. Effects of DNAzymes targeting aurora kinase A on the growth of human prostate cancer. Cancer Gene Ther, 2008, 15: 517–525
Zhang G, Luo X, Sumithran E, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene, 2006, 25: 7260–7266
Wu Y P, Yu L J, Mcmahon R, et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther, 1999, 10: 2847–2857
Kabuli M, Yin J A L, Tobal K. Targeting PML/RARα transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells. Hematol J, 2004, 5: 426–433
Dass C R, Galloway S J, Jonathan C M, et al. Involvement of c-jun in human liposarcoma growth: Supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther, 2008, 7: 1297–1301
de Bock C E, Lin Z, Itoh T, et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J, 2005, 272: 3572–3582
Wang Y F, Shen J N, Shang X F, et al. Ezrin mRNA target site selection for DNAzymes using secondary structure and hybridization thermodynamics. Tumor Biol, 2011, 32: 809–817
Dass C R, Galloway S J, Choong P F M. Dz13, a c-Jun DNAzyme, is a potent inducer of caspase-2 activation. Oligonucleotides, 2010, 20: 137–145
Quaranta V. Motility cues in the tumor microenvironment. Differentiation, 2002, 70: 590–598
Stec M J, Niewiarowska J, Nawrot M, et al. DNAzyme to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem, 2002, 277: 6779–6787
Zhang L, Gasper W J, Sanford A, et al. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res, 2002, 62: 5463–5469
Zhang G S, Dass C R, Sun L Q, et al. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst, 2004, 96: 683–696
Baylin S B, Herman J G, Graff J R, et al. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res, 1998, 72: 141–196
Brueckner B, Lyko F. DNA methyltransferase inhibitors: Old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci, 2004, 25: 551–554
Li W, Liu Z L, Yao S Z, et al. Label-free colorimetric assay for methyl-transferase activity based on a novel methylation-responsive DNAzyme strategy. Anal Chem, 2010, 82: 1935–1941
Benson V L, Khachigian L M, Lowe H C. DNAzymes and cardiovascular disease. Brit J Pharmacol, 2008, 154: 741–748
Tan M L, Choong P F M, Dass C R. DNAzyme delivery systems: Getting past first base. Expert Opin Drug Del, 2009, 6: 127–138
Tan M L, Dunstan D E, Friedhuber A M, et al. A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site. J Control Release, 2010, 144: 196–202
Dass C R, Choong P F M, Khachigian L M. DNAzyme technology and cancer therapy: Cleave and let die. Mol Cancer Ther, 2008, 7: 243–251
Chan C W S, Khachigian L M. DNAzymes and their therapeutic possibilities. Intern Med J, 2009, 39: 249–251
Dass C R. Deoxyribozymes: Cleaving a path to clinical trials. Trends Pharmacol Sci, 2004, 25: 395–397
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Xu, Z., Yang, L., Sun, L. et al. Use of DNAzymes for cancer research and therapy. Chin. Sci. Bull. 57, 3404–3408 (2012). https://doi.org/10.1007/s11434-012-5380-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-012-5380-z